Tissue Regenix Group plc

TRX.L · LSE
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income-£934£0-£281-£643
Dep. & Amort.£527£0£520£390
Deferred Tax£0£0£0£0
Stock-Based Comp.£143£0£0-£351
Change in WC-£2,346£0-£3,206£500
Other Non-Cash£2,408£0£1,601£1,470
Operating Cash Flow-£202£0-£1,366£1,365
Investing Activities
PP&E Inv.-£50£0-£261-£154
Net Acquisitions£0£0£0£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.-£542£0-£22-£169
Investing Cash Flow-£592£0-£283-£323
Financing Activities
Debt Repay.£512£0£3,352-£140
Stock Issued£0£0£82£59
Stock Repurch.£0£0£0£0
Dividends Paid£0£0£0£0
Other Fin. Act.-£514£0-£2,563-£483
Financing Cash Flow-£2£0£871-£564
Forex Effect-£6£0£8-£18
Net Chg. in Cash£1,413-£3,461£3,461£448
Supplemental Information
Beg. Cash£0£3,461£0£3,200
End Cash£1,413£0£2,738£3,648
Free Cash Flow-£252£0-£1,573£1,211
Tissue Regenix Group plc (TRX.L) Financial Statements & Key Stats | AlphaPilot